Benchtop System for Biomarker Discovery

An easy-to-use compact clinical system is designed for use in biomarker discovery and validation and peptide and protein profiling.

The ClinProt Micro system offers integrated sample preparation tools for biofluids and tissue extracts with comprehensive analysis, visualization, and model-building software. The system easily measures peptides and proteins that can be used to discover multi-marker panels or profile patterns indicative of specific diseases. These multi-marker panels or patterns have potentially better diagnostic specificity than single biomarkers.

The ClinProt Micro system is well-suited for cancer research and for clinical and diagnostics research laboratories engaged in biomarker discovery across a range of samples. The product of Bruker Daltonik, GmbH (Bremen, Germany), the system operates under the company's integrated Compass software for intuitive operation by expert and nonexpert users alike. The company's AnchorChip matrix-assisted laser absorption ionization (MALDI) target technology offers fast automated acquisition and a 10-100-fold sensitivity increase for biomarker discovery. The ClinProt Micro system can also be used for biomarker identification on isolated and digested putative biomarkers with good protein sequence coverage.

The ClinProt Micro system incorporates the company's magnetic bead sample preparation technology with functionalized surfaces to bind and enrich proteins and peptides. Sample preparation is facile, scaleable, and highly reproducible whether undertaken manually or under automation. Bruker Daltonik's dedicated software for biomarker discovery, called ClinPro Tools, allows easy access to ClinProt Micro data for rapid and comprehensive evaluation to mine potential biomarkers in complex protein profiles.

"ClinProt Micro offers a dedicated, scaleable system for biomarker discovery, which we believe will substantially increase the ability of cancer and other clinical researchers to discover, validate, and identify new multi-marker panels with higher disease specificity,” remarked Frank H. Laukien, Ph.D., president and CEO of Bruker Daltonics in the United States (Billerica, MA).




Related Links:
Bruker Daltonics